Movement Alert｜Iovance Biotherapeutics, Inc. Pre-Market Rise 11.01%, mNSCLC TIL Data Webcast and Q3 Revenue Growth Expectations Lift Sentiment

Market Focus10-29

On October 29, Iovance Biotherapeutics, Inc. rose 11.01% in Pre-Market Trading, trading at $16.42/share, with turnover of $194.9 thousand.

The clearest catalyst was the company’s announcement that it would host a webcast to present positive data for TIL therapy in metastatic non-small cell lung cancer and outline its broader precision medicine strategy, which directly increased market attention ahead of the session.

Supporting the move, the company previously raised its full-year revenue guidance to $410 million-$420 million from $350 million-$370 million, citing strong demand for Amtagvi and Proleukin. It is also scheduled to report quarterly results on November 5, with consensus expectations for revenue of $116 million, up 59.56% year over year, and adjusted EPS of negative $0.09, reflecting continued commercialization momentum and narrowing losses.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment